Effects of statin therapy on the progression of chronic kidney disease.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Advances in Chronic Kidney Disease

• Publication date

  2005-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/J.ACKD.2005.01.007PMID 15822054
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

  2015cited by this paper
• The metabolic syndrome and chronic kidney disease

  2006cited by this paper
• Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells.

  2004cited by this paper
• Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.

  2004cited by this paper
• Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

  2004cited by this paper
• Statin induced proteinuria: renal injury or renoprotection?

  2004cited by this paper
• Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics

  2004cited by this paper
• The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults

  2004cited by this paper
• Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated upregulation of p27.

  2004cited by this paper
• Cholesterol and the risk of renal dysfunction in apparently healthy men.

  2003cited by this paper
• Treating dyslipidemia to slow the progression of chronic renal failure.

  2003cited by this paper
• Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.

  2003cited by this paper
• Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.

  2003cited by this paper
• Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia.

  2003cited by this paper
• Derivation and differentiation of glomerular endothelial cells.

  2003cited by this paper
• Study of Heart and Renal Protection (SHARP).

  2003cited by this paper
• Epidemiology of cardiovascular risk in patients with chronic kidney disease.

  2003cited by this paper
• Statin-associated myopathy.

  2003cited by this paper
• Statins and renal function in patients with diabetes mellitus

  2003cited by this paper
• Statin Treatment in Diabetes Mellitus

  2003cited by this paper
• A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

  2003cited by this paper
• The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study

  2002cited by this paper
• Distinct Renal Injury in Early Atherosclerosis and Renovascular Disease

  2002cited by this paper
• 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy

  2002cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention

  2002cited by this paper
• A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin

  2002cited by this paper
• Potent Suppression of Proliferation of A10 Vascular Smooth Muscle Cells by Combined Treatment with Lovastatin and 3-Allylfarnesol, an Inhibitor of Protein Farnesyltransferase

  2002cited by this paper
• Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESDR patients.

  2002cited by this paper
• HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.

  2002cited by this paper
• Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation.

  2002cited by this paper
• Enhanced renal cortical vascularization in experimental hypercholesterolemia.

  2002cited by this paper
• Hyperlipidemia in kidney disease: causes and consequences

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment.

  2001cited by this paper
• Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits.

  2001cited by this paper
• Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells.

  2001cited by this paper
• Effect of lipid reduction on the progression of renal disease: a meta-analysis.

  2001cited by this paper
• Premature cardiovascular disease in chronic renal failure.

  2000cited by this paper
• Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure?

  2000cited by this paper
• Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects.

  2000cited by this paper
• Clinical Pharmacokinetics of Pravastatin

  2000cited by this paper
• Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

  2000cited by this paper
• Pharmacodynamics and Pharmacokinetic‐Pharmacodynamic Relationships of Atorvastatin, an HMG‐CoA Reductase Inhibitor

  2000cited by this paper
• Recent advances in statins and the kidney.

  1999cited by this paper
• Hyperlipidemia in patients with chronic renal disease.

  1998cited by this paper
• Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis.

  1998cited by this paper
• Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin

  1997cited by this paper
• Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency.

  1997cited by this paper
• Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study.

  1997cited by this paper
• Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.

  1996cited by this paper
• Effects of hypertension and dyslipidemia on the decline in renal function.

  1995cited by this paper
• Lipids and the kidney.

  1994cited by this paper
• Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia.

  1993cited by this paper
• Lipoprotein metabolism and renal failure.

  1993cited by this paper
• Lovastatin retards the progression of established glomerular disease in obese Zucker rats.

  1993cited by this paper
• Commonly measured laboratory variables in hemodialysis patients: relationships among them and to death risk.

  1992cited by this paper
• Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities.

  1990cited by this paper
• Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.

  1990cited by this paper
• Renal injury of diet-induced hypercholesterolemia in rats.

  1990cited by this paper
• Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats.

  1989cited by this paper
• Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis.

  1988cited by this paper
• Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats.

  1988cited by this paper
• Effects of genetic obesity on renal structure and function in the Zucker rat.

  1985cited by this paper
• Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease.

  1982cited by this paper

• Evaluation of Trace Elements in Augmentation of Statin-Induced Cytotoxicity in Uremic Serum-Exposed Human Rhabdomyosarcoma Cells

  2018cites this paper
• Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea

  2018cites this paper
• A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects.

  2015cites this paper
• Uremic Toxins Enhance Statin-Induced Cytotoxicity in Differentiated Human Rhabdomyosarcoma Cells

  2014cites this paper
• Clinical values of urinary IL-6 in asymptomatic renal hematuria and renal hematuria with proteins

  2013cites this paper
• Current views on the management of atherosclerotic renovascular disease

  2012cites this paper
• Diagnostic criteria for renovascular disease: where are we now?

  2012cites this paper
• Epidemiology and optimal management in patients with renal artery stenosis.

  2012cites this paper
• Contemporary management of atherosclerotic renovascular disease: Before and after ASTRAL

  2011influential citation
• Metabolismo oxidativo en niños y adolescentes con "diabetes mellitus" insulinodependiente: marcadores precoces de daño a moléculas y nefropatía diabética incipiente.

  2008cites this paper
• Fluvastatin inhibits activation of JAK and STAT proteins in diabetic rat glomeruli and mesangial cells under high glucose conditions

  2007cites this paper
• Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering

  2007cites this paper
• The Case for Disease Management in Chronic Kidney Disease

  2006cites this paper
• Obesidade e Doença Renal Crônica Obesity and Chronic Kidney Disease

  2006cites this paper
• Pharmacological management of renal fibrotic disease

  2006cites this paper